1.Effects of Induction Chemotherapy with BHAC Plus Idarubicin on Long-term Survival for Patients with Acute Myelogenous Leukemia according to Different Postremission Strategies.
Chun Choo KIM ; Jong Wook LEE ; Hee Je KIM ; Ki Won KIM ; Soo Jeong PARK ; Jung Gon SUH ; Chang Ki MIN ; Hyeon Seok EOM ; Young Seon HONG ; Woo Sung MIN ; Wan Shik SHIN ; Dong Jip KIM
Korean Journal of Hematology 1999;34(2):317-325
No abstract available.
Humans
;
Idarubicin*
;
Induction Chemotherapy*
;
Leukemia, Myeloid, Acute*
2.Combination chemotherapy with cytosine arabinoside and idarubicin for acute myelogenous leukemia.
Hyun Choon SHIN ; Chul Won JUNG ; Jin Hak LEE ; Jung Ae LEE ; Sung Hyun YANG ; Young Hyuk LEEM ; Seon Yang PARK ; Byoung Kook KIM ; Noe Kyoung KIM
Korean Journal of Hematology 1993;28(2):247-255
No abstract available.
Cytarabine*
;
Cytosine*
;
Drug Therapy, Combination*
;
Idarubicin*
;
Leukemia, Myeloid, Acute*
3.Renission induction chemotherapy with idarubicin and cytosine arabinoside for the patients with acute myelogenous leukemia.
Jong Youl JIN ; Hyun Suk UHM ; Doo Soo JEON ; Jong Wook LEE ; Chi Hwa HAN ; Woo Sung MIN ; Chong Won PARK ; Chun Choo KIM ; Dong Jip KIM ; Woo Kun CHOI ; Hack Ki KIM
Korean Journal of Hematology 1991;26(2):281-287
No abstract available.
Cytarabine*
;
Cytosine*
;
Humans
;
Idarubicin*
;
Induction Chemotherapy*
;
Leukemia, Myeloid, Acute*
4.NT-pro-BNP in the evaluation of daunorubicin-indued cardiotoxicity in acute childhood leukemia.
Chinese Journal of Hematology 2010;31(9):621-623
OBJECTIVETo evaluate the sensitivity of NT-pro-BNP in daunorubicin (DNR) induced myocardial damage by monitoring the level of NT-pro-BNP and myocardial enzymes (CK, CKMB) before and after DNR treatment in childhood acute leukemia (AL) and performing control study.
METHODSSixty-two cases (total 194 samples) which diagnosed as primary AL were enrolled and had received the conventional chemotherapy. According to the cumulative dose of DNR, they were divided into three groups: cumulative dose ≤ 60 mg/m(2) (group A); cumulative dose 60 - 120 mg/m(2) (group B); cumulative dose > 120 mg/m(2) (group C) and 15 cases with idarubicin (IDA) or mitoxantrone (MXR) as altervative to DNR (group D).
RESULTSThere was a significant difference (P = 0.000) in the level of NT-pro-BNP before and after DNR therapy, but did not in the myocardial enzymes activities (CK, P = 0.085 and CKMB, P = 0.076). The level of NT-pro-BNP appeared obviously elevated (P = 0.001) when DNR cumulative dose > 60 mg/m(2). While the level of CKMB did (P = 0.022) until DNR cumulative dose > 120 mg/m(2). In the 15 cases used IDA or MXR as alternative to DNR, the level of NT-pro-BNP fall from (239.9 ± 230.0) ng/L to (137.0 ± 131.9) ng/L (P = 0.024).
CONCLUSION(1) Compared with myocardial enzymes detection, NT-pro-BNP level can predict earlier DNR-induced cardiotoxicity. (2) Selection of the second or third generation anthracycline to treat AL can significantly reduce the cardiotoxicity in children.
Anthracyclines ; Cardiotoxicity ; Daunorubicin ; administration & dosage ; Humans ; Idarubicin ; administration & dosage ; Leukemia ; drug therapy
5.Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML.
Peng LIN ; Wei WANG ; Wei-Bo HUANG ; Ming-Wei LI ; Xiao-Na YANG ; Hai-Ying YAO
Journal of Experimental Hematology 2018;26(2):422-426
OBJECTIVETo compare the complete remission rate (CRR) and adverse reaction of the 3 different chemotherapy regimens (daunorubicin, idarubicin, imported idarubicin combined with cytarabine) for the treatment of adult patients with newly diagnosed non-M3 acute myeloid leukemia (AML).
METHODSSeventy-one adult patients with newly diagnosed non-M3 AML were divided into 3 groups: 17 cases treated with daunorubicin plus cytarabine as group A, 24 cases treated with idarubicin plus cytarabine as group B, 30 cases treated with the imported idarubicin plus cytarabine as group C. The curative effects and adverse reactions were compared among the 3 groups after treatment.
RESULTSCCR in group C (86.67%) was significantly higher than that in group A (52.94%) and group B (70.83%), and the CRR in group B was significantly higher than that in group A (P<0.05). The incidence of adverse reaction such as nausea, vomiting, myelosuppression and infection among 3 groups were not statistically significantant (P>0.05).
CONCLUSIONThe curative effect of idarubicin for the treatment of non-M3 AML patients is better than that of daunorubicin, especially the curative efficiency of imported darubicin is much higher; the adverse reaction after treatment by daunorubicin and idarubicin can be controllable, so daunorubicin and idarubicin can be used as first-line drug for the patients with AML, and patients can choose more appropriate drug according to their own economic ability.
Adult ; Antineoplastic Combined Chemotherapy Protocols ; Cytarabine ; Daunorubicin ; Humans ; Idarubicin ; Leukemia, Myeloid, Acute ; Remission Induction
6.Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.
Jae Ho YOON ; Hee Je KIM ; Dae Hun KWAK ; Gi June MIN ; Sung Soo PARK ; Young Woo JEON ; Sung Eun LEE ; Byung Sik CHO ; Ki Seong EOM ; Yoo Jin KIM ; Seok LEE ; Chang Ki MIN ; Seok Goo CHO ; Dong Wook KIM ; Jong Wook LEE ; Woo Sung MIN
Blood Research 2017;52(3):174-183
BACKGROUND: Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult acute myeloid leukemia (AML). However, the effects of intensified regimen on complete remission (CR), relapse and overall survival (OS) remain unknown. METHODS: We analyzed 1195 patients treated with idarubicin plus cytarabine/BHAC (3+7) from 2002 to 2013. Among them, 731 received early intensification with 3-day cytarabine/BHAC (3+10, N=363) or 2-day idarubicin plus cytarabine/BHAC 3 days (5+10, N=368). The 3+10 and 5+10 strategies were applied to patients with bone marrow blast counts of 5–20% and >20% on day 7 of 3+7, respectively. RESULTS: Early intensification correlated with a younger age (median: 40 vs. 45 yr) and higher t(8;21) frequency (20.4% vs. 7.1%), compared to 3+7. After early intensification, the early death rates were higher among the elderly (3+10 [15.7%], 5+10 [21.7%] vs. 3+7 [6.3%], P=0.038), while the post-induction CR rate was higher in young patients (3+10 [79.8%], 5+10 [75.1%] vs. 3+7 [65.1%], P<0.001). Early relapse rate was also decreased (3+10 [11.8%], 5+10 [11.7%] vs. 3+7 [22.0%], P<0.001). In multivariate analysis, early intensification correlated with an inferior 5-year OS among elderly patients (19.2% vs. 22.8%; hazard ratio [HR]=1.84, 95% confidence interval [CI]; 1.11–3.06, P=0.018) and lower overall relapse rate among young patients (33.0% vs. 41.4%, P=0.023; HR=0.71, 95% CI; 0.55–0.93, P=0.012). CONCLUSION: Early intensification correlated with higher CR and lower relapse rates, but not OS in young AML patients. In elderly patients, early intensification correlated with a higher early death rate and poorer OS.
Adult*
;
Aged
;
Bone Marrow
;
Cytarabine
;
Drug Therapy*
;
Humans
;
Idarubicin
;
Induction Chemotherapy*
;
Leukemia, Myeloid, Acute*
;
Mortality
;
Multivariate Analysis
;
Recurrence
;
Remission Induction
7.The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia.
Young Joo MIN ; Cheol Won SUH ; Keon Uk PARK ; Sung Soo YOON ; Chan Hyung PARK ; Hong Ghi LEE
Cancer Research and Treatment 2003;35(1):66-68
PURPOSE: This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML). MATERIALS AND METHODS: After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200mug/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1, 000/muL for 3 consecutive days. RESULTS: The median time from the initiation of the chemotherapy to the neutrophil recovery of 1, 000/muL was 21 days (range, 12~41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%). CONCLUSION: The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML.
Cytarabine
;
Drug Therapy*
;
Granulocyte Colony-Stimulating Factor
;
Granulocytes*
;
Headache
;
Humans*
;
Idarubicin
;
Leukemia, Myeloid, Acute*
;
Neutropenia*
;
Neutrophils
;
Remission Induction*
8.Clinical significance of PML/RAR alpha isoforms in acute promyelocytic leukemia.
Won Sik LEE ; Sang Min LEE ; Kyoo Hyung LEE ; Je Hwan LEE ; Seong Joon CHOI ; Jung Hee LEE ; Dae Young KIM ; Sung Nam LIM ; Jae Hoo PARK ; Young Joo MIN ; Hawk KIM ; Sung Hwa BAE ; Hun Mo RYOO ; Myung Soo HYUN ; Min Kyung KIM ; Dae Young ZANG ; Hyo Jung KIM ; Chul Won JUNG ; Jin Seok AHN ; Kyeong Won LEE ; Jung Lim LEE ; Young Don JOO
Korean Journal of Medicine 2008;75(4):412-419
BACKGROUND/AIMS: There are three types of PML-RAR alpha mRNA fusion transcripts associated with acute promyelocytic leukemia (APL): the short (S)-form, the long (L)-form and the variable (V)-form. No study on the Korean population has addressed the clinical significance of the specific types of PML-RAR alpha mRNA fusion transcripts for APL patients who receive the combination therapy of all-trans-retinoic-acid and idarubicin (AIDA regimen). METHODS: We performed a retrospective analysis on 94 patients with APL to evaluate differences in the therapeutic outcomes, such as the response rate, an event-free survival (EFS), and overall survival (OS), after remission following the induction of chemotherapy. We also analyzed whether differences in the pretreatment clinical characteristics depend on the PML-RAR alpha isoform. RESULTS: The median age of the patients was 41 years (range 15-85). Among the 94 patients, there were 58 L-form cases (62.1%), 32 S-form cases (34.0%), and 4 V-form cases (4.3%). The CR rate following remission induction treatment was 84.9%. The CR rate was higher in patients with an initial WBC <10.0x109/L, as compared to patients with an initial WBC higher than 10.0X109/L (93.5% vs. 65.4%, p=0.001). The AIDA induction regimen was associated with a better EFS than non-AIDA induction regimens (81.9% vs. 49.6%, p=0.006). The induction group was also a significant prognostic factor for EFS in the multivariate analysis (p=0.020). There were no differences in OS and EFS in patients with either isoform L or isoform S in the AIDA induction group. CONCLUSIONS: This retrospective study demonstrated that pretreatment clinical characteristics and treatment outcomes were not significantly different among patients with varying PML-RAR alpha isoform types in the AIDA induction group.
Disease-Free Survival
;
Humans
;
Idarubicin
;
Leukemia, Promyelocytic, Acute
;
Multivariate Analysis
;
Protein Isoforms
;
Remission Induction
;
Retrospective Studies
;
RNA, Messenger
9.Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia.
Yuanyuan ZHANG ; Shenmiao YANG ; Jing WANG ; Honghu ZHU ; Li BAO ; Jinsong JIA ; Ting ZHAO ; Hao JIANG ; Jin LU ; Bin JIANG ; Xiaojun HUANG ; Qian JIANG
Chinese Journal of Hematology 2015;36(3):225-229
OBJECTIVETo compare the efficacy and toxicity of 10 mg/m² or 8 mg/m² idarubicin (Ida) combined with cytarabine (IA"3+7"regimen) as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia (AML).
METHODSFrom June 2004 to October 2013, 335 adult AML (non acute promyelocytic leukemia) patients receiving the IA regimen as induction chemotherapy were enrolled, including 198 cases with 10 mg/m² Ida and 137 cases with 8 mg/m² Ida for 3 days. We compared the hematologic response, hematologic side effects and prognosis between the two regimens.
RESULTSExcept for 4 early deaths, the complete remission (CR) rate after the first cycle of induction chemotherapy was 72.5%, 10.0% partial remission (PR) and 82.5% overall remission (OR) rate. The CR and OR rates were higher in the 10 mg/m² Ida group than the 8 mg/m² Ida group (CR: 78.9% vs 63.5%, P=0.003; OR: 88.2% vs 75.4%, P=0.007). Multivariate analysis showed that female, HGB≥100 g/L, FLT3-ITD mutation negative and 10 mg/m² Ida were favorable factors for CR. All patients presented cytopenias of grade Ⅳ. There was no differences on the recovery time of ANC≥0.5×10⁹/L and PLT≥20×10⁹/L after induction chemotherapy. Within a median follow-up of 14 (1-118) months, 98 (29.3%) patients relapsed, 92 (27.5%) died. The disease-free survival (DFS) and overall survival (OS) at 3 years were 53.2% and 58.9%, respectively. DFS and OS at 3-year were 34.2% and 37.4% in the chemotherapy cohort, 74.5% and 81.2% in the transplant cohort. 10 mg/m² Ida was an independent favorite factor for DFS (P=0.040) and OS (P=0.007).
CONCLUSIONAs compared to 8 mg/m², 10 mg/m² Ida significantly improved the CR, with the same extent of hematological side effects, and was an independent favorite factor for DFS and OS.
Adult ; Antineoplastic Combined Chemotherapy Protocols ; Cytarabine ; Disease-Free Survival ; Female ; Humans ; Idarubicin ; Induction Chemotherapy ; Leukemia, Myeloid, Acute ; Prognosis ; Remission Induction
10.Comparison of Combination Induction Chemotherapy using Idarubicin Plus either Enoron(r) or Sunrabin(r) in Adult Patients with Acute Myeloid Leukemia.
Hee Je KIM ; Woo Sung MIN ; Yoon Hee PARK ; Yoo Jin KIM ; Seok LEE ; Dong Wook KIM ; Jong Wook LEE ; Chun Choo KIM
Korean Journal of Hematology 2004;39(1):10-15
BACKGROUND: To evaluate the effects and toxicity of combination chemotherapy using idarubicin (IDA) plus BH-AC as an induction regimen, we studied two groups of patients with adult acute myeloid leukemia (AML) who received IDA plus either Sunrabin(r) or Enoron(r). METHODS: Twenty-four and twenty-five patients in each group eligible for the induction study were enrolled. The remission induction therapy consisted of IDA 12mg/m2 intravenously for three consecutive days in combination with two kinds of BH-AC, that is Sunrabin(r) or Enoron(r), 300mg/m2 intravenously for seven days. Additional augmentation treatment with BH- AC was given for 3 days based on the results of bone marrow examination performed on the seventh day following initial treatment, i.e. depending on the ratio of the remaining leukemic cells. RESULTS: Complete remission was achieved in 75% vs 74% of each group of patients. The treatment-related mortality during induction chemotherapy was 1 patient in each group. There was no statistical difference in the level of toxicities between two groups. The most frequent side effect after these combination chemotherapy was manageable mucositis. Enoron(r) group showed rather rapid recovery of peripheral blood counts than those of Sunrabin(r) group. CONCLUSION: This study indicate Enoron(r) is comparable to Sunrabin(r) which can be used as an effective induction chemotherapeutic agent in adult patient with AML.
Adult*
;
Bone Marrow Examination
;
Drug Therapy, Combination
;
Humans
;
Idarubicin*
;
Induction Chemotherapy*
;
Leukemia, Myeloid, Acute*
;
Mortality
;
Mucositis
;
Remission Induction